Merck and Moderna report positive Phase 3 trial results for personalized melanoma vaccine

Merck and Moderna announced that their personalized mRNA cancer vaccine successfully reduced the recurrence and spread of melanoma in a trial of over 1,000 patients. While the results represent a significant clinical milestone for personalized immunotherapy, the timeline for regulatory approval and commercial scalability remains uncertain.